From Insights to Impact: Rare Disease Therapies with UCB’s Dr. Kim Moran

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Kim Moran, PhD, Senior Vice President & Head, Rare Diseases US, UCB, a company focused on neurological and immune-mediated inflammatory diseases, as well as developing therapies for rare genetic disorders such as the mitochondrial disease thymidine kinase 2 deficiency (TK2d). Dr. Moran has been at UCB for over 17 years where she has led US digital business transformation and most recently served as Head of Insights to Impact, a role she originated to translate patient insights into strategic and operational impact. She has held multiple leadership roles across neurology and epilepsy strategy, and led lifecycle and medical affairs initiatives for key products. Dr. Moran has received multiple leadership awards, including HBA Rising Star, a PM360 Pharma Choice Award and recognition by Medical Marketing + Media as a Woman to Watch (2019) and Woman of Distinction (2024). She is a CHIEF member, a Women in Bio Boardroom Ready alumna and serves on the board of Nile AI. She holds an Executive Global MBA from INSEAD, a PhD in Neuroscience and Physiology from New York University and a Bachelor of Science (BS) in Biochemistry and Molecular Biology from Penn State University. Tune in to hear Dr. Moran discuss the evolving rare disease landscape, how patient insights are shaping strategy and what it takes to bring innovative therapies to underserved populations. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured